CA3008749C - Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin - Google Patents

Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin Download PDF

Info

Publication number
CA3008749C
CA3008749C CA3008749A CA3008749A CA3008749C CA 3008749 C CA3008749 C CA 3008749C CA 3008749 A CA3008749 A CA 3008749A CA 3008749 A CA3008749 A CA 3008749A CA 3008749 C CA3008749 C CA 3008749C
Authority
CA
Canada
Prior art keywords
benzoxy
alaninyl
phosphate
gemcitabine
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3008749A
Other languages
English (en)
French (fr)
Other versions
CA3008749A1 (en
Inventor
Hugh GRIFFITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2015/054158 external-priority patent/WO2017109444A1/en
Priority claimed from GBGB1609770.1A external-priority patent/GB201609770D0/en
Application filed by Nucana PLC filed Critical Nucana PLC
Publication of CA3008749A1 publication Critical patent/CA3008749A1/en
Application granted granted Critical
Publication of CA3008749C publication Critical patent/CA3008749C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3008749A 2015-12-23 2016-12-21 Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin Active CA3008749C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (en) 2015-12-23 2015-12-23 Combination therapy
GBPCT/GB2015/054158 2015-12-23
GBGB1609770.1A GB201609770D0 (en) 2016-06-03 2016-06-03 Combination therapy
GB1609770.1 2016-06-03
PCT/GB2016/054018 WO2017109486A1 (en) 2015-12-23 2016-12-21 Combination therapy

Publications (2)

Publication Number Publication Date
CA3008749A1 CA3008749A1 (en) 2017-06-29
CA3008749C true CA3008749C (en) 2024-01-02

Family

ID=57681677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3008749A Active CA3008749C (en) 2015-12-23 2016-12-21 Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin

Country Status (29)

Country Link
US (2) US20190022117A1 (enExample)
EP (2) EP3738595A1 (enExample)
JP (1) JP6898329B2 (enExample)
KR (1) KR20180096698A (enExample)
CN (1) CN108697725A (enExample)
AU (1) AU2016375861B2 (enExample)
CA (1) CA3008749C (enExample)
CY (1) CY1122835T1 (enExample)
DK (1) DK3393478T3 (enExample)
EA (1) EA037459B1 (enExample)
ES (1) ES2778933T3 (enExample)
HR (1) HRP20200423T1 (enExample)
HU (1) HUE050290T2 (enExample)
IL (1) IL260076A (enExample)
LT (1) LT3393478T (enExample)
MA (1) MA51576A (enExample)
MD (1) MD3393478T2 (enExample)
ME (1) ME03677B (enExample)
MX (1) MX383988B (enExample)
MY (1) MY194629A (enExample)
PH (1) PH12018501339A1 (enExample)
PL (1) PL3393478T3 (enExample)
PT (1) PT3393478T (enExample)
RS (1) RS60211B1 (enExample)
SG (1) SG11201805184TA (enExample)
SI (1) SI3393478T1 (enExample)
SM (1) SMT202000154T1 (enExample)
WO (1) WO2017109486A1 (enExample)
ZA (1) ZA201804155B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EA201491629A1 (ru) * 2012-08-13 2015-08-31 Регулон, Инк. Способы лечения рака с использованием липоплатина
JP6420247B2 (ja) * 2012-11-13 2018-11-07 ボーイエン セラピューティクス，インコーポレイティド ゲムシタビンプロドラッグ及びその使用
CN107835687A (zh) * 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy

Also Published As

Publication number Publication date
US20190022117A1 (en) 2019-01-24
JP2019509253A (ja) 2019-04-04
MX2018007772A (es) 2019-07-04
WO2017109486A1 (en) 2017-06-29
SMT202000154T1 (it) 2020-05-08
HK1255110A1 (en) 2019-08-02
US20230149436A1 (en) 2023-05-18
ME03677B (me) 2020-10-20
KR20180096698A (ko) 2018-08-29
EA201891473A1 (ru) 2019-01-31
MA51576A (fr) 2020-11-18
PH12018501339A1 (en) 2019-02-18
ZA201804155B (en) 2021-06-30
LT3393478T (lt) 2020-04-10
DK3393478T3 (da) 2020-03-23
MY194629A (en) 2022-12-07
EP3738595A1 (en) 2020-11-18
CY1122835T1 (el) 2021-05-05
AU2016375861B2 (en) 2021-12-23
MX383988B (es) 2025-03-14
MD3393478T2 (ro) 2020-04-30
PL3393478T3 (pl) 2020-07-13
BR112018012956A2 (pt) 2019-01-08
PT3393478T (pt) 2020-03-24
JP6898329B2 (ja) 2021-07-07
CN108697725A (zh) 2018-10-23
CA3008749A1 (en) 2017-06-29
SG11201805184TA (en) 2018-07-30
RS60211B1 (sr) 2020-06-30
HRP20200423T1 (hr) 2020-09-04
SI3393478T1 (sl) 2020-07-31
HUE050290T2 (hu) 2020-11-30
IL260076A (en) 2018-07-31
EP3393478A1 (en) 2018-10-31
ES2778933T3 (es) 2020-08-12
EA037459B1 (ru) 2021-03-30
EP3393478B1 (en) 2020-03-04
AU2016375861A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
US20220323475A1 (en) Combination therapy for cancer
US20230149436A1 (en) Combination therapy
AU2015418015B2 (en) Combination therapy
BR112016025787B1 (pt) Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
US20200197430A1 (en) Combination Therapy
HK40038228A (en) Combination therapy
HK1255110B (en) Combination therapy
NZ743529A (en) Combination therapy
BR112018012956B1 (pt) Uso de gencitabina-[fenil-(benzóxi-l-alaninil)]-fosfato ou um sal ou solvato farmaceuticamente aceitável do mesmo no tratamento de câncer
BR112018006880B1 (pt) Uso de gencitabina-[fenil-benzóxi-l-alaninil)]-fosfato ou um sal farmaceuticamente aceitável ou solvato da mesma e carboplatina no tratamento de câncer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211214